Eli Lilly and Company (LLY) Stock Price, News & Analysis

Company Overview

Eli Lilly and Company is a global pharmaceutical firm headquartered in Indianapolis, Indiana, that discovers, develops, manufactures and markets human pharmaceuticals in a wide range of therapeutic areas. The company’s core focus includes neuroscience, endocrinology, oncology, immunology and cardiovascular disease. Through a vertically integrated research and development model, Eli Lilly advances novel small molecules and biologics from early research through commercialization, serving both adult and pediatric patient populations.

Founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War, the company has grown from a regional drug manufacturer into one of the world’s leading innovators in life sciences. Early achievements included the introduction of insulin for diabetes management in the 1920s and penicillin production during World War II. Over more than a century of operation, Eli Lilly has been credited with pioneering contributions to psychopharmacology, hormone therapies and targeted cancer treatments.

Key marketed products span several disease areas: in diabetes care, it offers rapid- and long-acting insulins as well as injectable GLP-1 receptor agonists; in oncology, its portfolio includes small-molecule kinase inhibitors and immuno-oncology antibodies; and in immunology, the company develops therapies for inflammatory conditions such as rheumatoid arthritis and psoriasis. Complementing these marketed drugs, Lilly maintains an active pipeline with candidates advancing across multiple phases of clinical trials.

Eli Lilly serves patients in more than 120 countries through a combination of direct operations and partnerships. The company emphasizes global manufacturing and supply chain resilience, with major production sites in North America, Europe and Asia. Under the leadership of President and Chief Executive Officer David A. Ricks, Lilly continues to invest heavily in research collaborations, digital health solutions and initiatives to expand access to medicines worldwide.

Key Stats

• Today's Range: $725.31 to $761.58
• 50-Day Range: $625.15 to $811.73
• 52-Week Range: $623.78 to $937.00
• Volume: 3.52 million shs
• Average Volume: 4.08 million shs
• Market Capitalization: $723.11 billion
• P/E Ratio: 49.83
• Dividend Yield: 0.79%
• Price Target: $939.61
• Consensus Rating: Moderate Buy

Eli Lilly and Company Stock Analysis - MarketRank™

Eli Lilly and Company scored higher than 100% of companies evaluated by MarketBeat, and ranked 3rd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Eli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 14 buy ratings, 9 hold ratings, and no sell ratings.

Upside Potential

Eli Lilly and Company has a consensus price target of $939.61, representing about 27.7% upside from its current price of $735.80.

Amount of Analyst Coverage

Eli Lilly and Company has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 32.54%

Earnings Growth

Earnings for Eli Lilly and Company are expected to grow by 32.54% in the coming year, from $23.48 to $31.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eli Lilly and Company is 48.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.76.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eli Lilly and Company is 48.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.55.

Price to Earnings Growth Ratio

Eli Lilly and Company has a PEG Ratio of 1.01. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

Eli Lilly and Company has a P/B Ratio of 48.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.86% of the float of Eli Lilly and Company has been sold short.

Short Interest Ratio / Days to Cover

Eli Lilly and Company has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eli Lilly and Company has recently decreased by 8.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Eli Lilly and Company has a dividend yield of 0.84%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Eli Lilly and Company has been increasing its dividend for 11 years.

Dividend Coverage

The dividend payout ratio of Eli Lilly and Company is 39.22%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 19.28% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -2.25

Percentage of Shares Shorted

0.86% of the float of Eli Lilly and Company has been sold short.

Short Interest Ratio / Days to Cover

Eli Lilly and Company has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eli Lilly and Company has recently decreased by 8.96%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.98

News Sentiment

Eli Lilly and Company has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 153 news articles for Eli Lilly and Company this week, compared to 67 articles on an average week.

Search Interest

Only 236 people have searched for LLY on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.

MarketBeat Follows

Only 83 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is a decrease of -23% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Eli Lilly and Company insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,894,841.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.13% of the stock of Eli Lilly and Company is held by insiders.

Percentage Held by Institutions

82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LLY Stock Analysis - Frequently Asked Questions

How have LLY shares performed this year?

Eli Lilly and Company's stock was trading at $772.00 on January 1st, 2025. Since then, LLY shares have decreased by 4.7% and is now trading at $735.80.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) posted its quarterly earnings data on Thursday, August, 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company's revenue was up 37.6% on a year-over-year basis.
Read the conference call transcript.

Is Eli Lilly and Company buying back stock?

Eli Lilly and Company's Board of Directors initiated a stock repurchase program on Monday, December 9th 2024, which authorizes the company to repurchase $15,000,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's management believes its shares are undervalued.

Does Eli Lilly and Company have any subsidiaries?

Eli Lilly and Company subsidiaries include Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and others.

How do I buy shares of Eli Lilly and Company?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eli Lilly and Company own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include Broadcom (AVGO), NVIDIA (NVDA), Meta Platforms (META), BlackRock (BLK), Salesforce (CRM), Chevron (CVX) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/07/2025
• Record date for 9/10 Dividend: 8/15/2025
• Ex-Dividend for 9/10 Dividend: 8/15/2025
• Dividend Payable: 9/10/2025
• Today: 9/30/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:LLY
• CIK: 59478
• Web: www.lilly.com
• Phone: (317) 276-2000
• Fax: 317-276-4878
• Employees: 47,000
• Year Founded: 1876

Price Target and Rating

• Average Price Target for Eli Lilly and Company: $939.61
• High Price Target: $1,190.00
• Low Price Target: $700.00
• Potential Upside/Downside: +29.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $15.30
• Trailing P/E Ratio: 47.42
• Forward P/E Ratio: 30.90
• P/E Growth: 1.01
• Net Income: $10.59 billion
• Net Margins: 25.91%
• Pretax Margin: 31.66%
• Return on Equity: 92.72%
• Return on Assets: 16.89%

Debt

• Debt-to-Equity Ratio: 1.86
• Current Ratio: 1.28
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $53.26 billion
• Price / Sales: 12.89
• Cash Flow: $14.25 per share
• Price / Cash Flow: 50.90
• Book Value: $15.03 per share
• Price / Book: 48.27

Miscellaneous

• Outstanding Shares: 946,457,000
• Free Float: 945,132,000
• Market Cap: $686.69 billion
• Optionable: Optionable
• Beta: 0.47